发明名称 Silicone-based composition for skin treatment
摘要 The present embodiments may relate to topically delivered compounded medications for the treatment of scar tissue, skin disorders, and/or other ailments. In one aspect, a transdermal cream or gel may provide for the effective administration of multiple medications simultaneously. Preferably, a silicone-based gel may be provided as a base composition and may have a non-zero percentage of silicone or silicone variant. The silicone-based gel may comprise cyclopentasiloxane, polysilicone-11, dimethicone, and C30-45 alkyl cetearyl dimethicone crosspolymer, and include several active ingredients, such as glucocorticoids, antihistamines, and nerve depressants. The silicone-based gel may include a combination of fluticasone, loratadine, and gabapentin. The concentrations of fluticasone and loratadine may be relatively low, while that of gabapentin moderately high. The silicone-based gel may also have one or more local anesthetics, such as prilocaine and/or lidocaine. The silicone-based gel may include additional active ingredients, such as NSAIDs, anticonvulsants, antidepressants, muscle relaxants, and/or other active ingredients.
申请公布号 US9592241(B2) 申请公布日期 2017.03.14
申请号 US201213564467 申请日期 2012.08.01
申请人 CMPD LICENSING, LLC 发明人 Ray, II Jay Richard;Hodge Charles D.
分类号 A61K31/56;A61K31/167;A61K31/195;A61K31/4545;A61K31/695;A61K9/00;A61K47/24;A61K9/06;A61K47/34;A61K45/06 主分类号 A61K31/56
代理机构 Akerman LLP 代理人 Akerman LLP
主权项 1. A silicone-based gel for topical application and treatment of scar tissue, the silicone-based gel comprising: cyclopentasiloxane, polysilicone-11, dimethicone and C30-45 alkyl cetearyl dimethicone crosspolymer; a first active ingredient in a first amount of between approximately 0.1% and approximately 5.0% by weight of the silicone-based gel, the first active ingredient comprising a fluticasone; a second active ingredient in a second amount of between approximately 0.1% and approximately 5.0% by weight of the silicone-based gel, the second active ingredient comprising loratadine; a third active ingredient in a third amount of between approximately 5.0% and approximately 25.0% by weight of the silicone-based gel, the third active ingredient comprising gabapentin; and lidocaine and prilocaine each in an amount of between approximately 1.0% and approximately 7.0% by weight of the silicone-based gel, wherein the topical application of the silicone-based gel allows for transdermal administration of the active ingredients simultaneously.
地址 Conroe TX US